Brussels recognize Ligonmef drug against Alzheimer’s team in some patient groups

The European Commission (CE) This Tuesday has been recognized The use of lecanmef drug In Union In the early stages of Alzheimer’s disease, under severe conditions, clear risk reduction requirements and only some patient groups to treat mild cognitive decline.

“It is used among persons There is nothing in a copy or APOE4 gene The brain contains amyloid beta plates. This is the first drug recognized in the EU, ”the European Commission said.

Brussels’ green lighting comes after the Human Utilization Drugs Committee After the previously advised Considering that side effects of delayed delay in cognitive impairment are not compensated.

In a statement, EMA noted that the recognition of marketing this drug as a treatment for cognitive deficiency or Lightened dementia following Alzheimer’s This is “patients with only a copy or APOE4, a particular form of apolipoprotein and” protein gene “.”

“Patients who do not have a single copy or a copy of APOE4 They are less likely to experience image contradictions People with two copies of APOE4 are related to ARIA. Area is an extreme side effect with Legbery, which refers to inflammation and brain bleeding, ”Ema said.

Skepticism

United States Food and Drug Administration (FDA, English) The use of this drug was recognized a year ago It slows down the symptoms of Alzheimer, which is an irreversible neurodegenerative disease that destroys memory and the ability to perform tasks. But the drug administered through the nerve is suspicious because of that opportunity Causing inflammation and bleeding In the brain, a condition that occurs in some Alzheimer’s patients called ARIA.

Therefore, the Committee for EMA’s Human Utilities Drugs decided that in July the European Commission Should not be given a marketing license to the drugThe Japanese pharmacist was developed by Easy and it was effective when the effects of neurotransmitism were reduced.

However, after reviewing the medication in a small population, the EMA concludes that the patient’s profile “to reduce the progress of the disease is to reduce the progress of the disease.” They are more than their risks ” They are accepted Time “Risk Reduces Reductions” The most serious side effects.

The need to manage this treatment, patients will have to do Magnetic vibrations Before taking the first, fifth, seventh and fourteenth tose of the drug, if they show the symptoms of cerebral inflammation described at any other time, headache, dizziness or nausea.